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Strokea b s t r a c t
High sensitivity C-reactive protein (hsCRP) has been evaluated as a biomarker in stroke and relevant
pathological diseases. While its predictive values in several pathological phenotypes have been con-
firmed, controversy exists among different studies. This review summarizes reports of the predictive val-
ues of hsCRP for the diagnosis, etiology, prognosis and mortality of stroke diseases. The current literature
suggests that CRP expression is influenced by multiple factors, such as polymorphisms, the genomic
backgrounds and gender. However, few reported studies analyzed data based on all these multiple fac-
tors. Future studies should focus on comprehensive analysis based on multiple factors.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Stroke is a major cerebrovascular disease threatening human
health and life with high morbidity, disability and mortality [1].
According to the data from Global Burden of Disease Study [2],
worldwide in 2010 there were an estimated 11,569,538 incident
ischemic strokes and 5,324,997 events of incident hemorrhagic
stroke; furthermore, 2,835,419 individuals died from ischemic
stroke and 3,038,763 from hemorrhagic stroke. Stroke is the num-
ber cause of the death in several countries such as China [3]. Stroke
was defined as a sudden onset of loss of global or focal cerebral
function persisting for more than 24 h [4]. Biomarkers that predict
the occurrence and outcome from ischemic stroke are critical for
prevention and treatment. Serum biomarkers are considered to
be the most valuable adjunct to routine clinical examination and
imaging data [5]. Inflammation has an important role in the devel-
opment of atherosclerosis and during the ischemic event. Inflam-matory markers such as fibrinogen and hsCRP have been
reported as a predictable marker for the stroke severity and out-
come [6]. It has been reported that it is possible to use the increase
in the concentration of acute phase reactants especially the hsCRP
to help predict cerebrovascular mortality [7].
Human CRP (Pentraxin 1, Ptx1) is an acute phase reactant that is
rapidly produced by the liver after tissue injury or infection [5,7].
CRP is a sensitive indicator of inflammation [8,9]. Although many
inflammatory biomarkers have been reported to be useful in pre-
dicting clinical outcome after stroke, hsCRP remains one of the
most widely used in clinical practice [8–12]. Increased hsCRP has
been associated with the development of atherosclerosis, ischae-
mic attacks, hemorrhagic stroke, as well as disease outcomes
[13–17]. Studies suggest that post-stroke inflammatory responses
may exacerbate tissue damage after cerebral infarction and affect
clinical outcomes [18,19]. Recent studies have shown that elevated
hsCRP values independently predict the risk of future cardiovascu-
lar diseases and ischemic cerebrovascular diseases, including tran-
sient ischemic attack in the elderly [20–22]. After acute ischemic
stroke (AIS), a sustained inflammatory response indicated by
increased level of CRP has been reported in about 75% of patients.
A strong and persistent inflammatory response is associated with a
worse outcome. Moreover, CRP at discharge has been shown to be
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suggested that elevated baseline hsCRP levels are independently
associated with excessive ischemic stroke risk.
However, the physiologic role of CRP is not well understood; it
potentially has anti-inflammatory properties as well as pro-
inflammatory effects [26]. Inflammation may not only be the con-
sequence of brain infarction, it may also contribute to ischemic
damage. In addition, the role of inflammatory markers in predict-
ing functional outcome in stroke remains controversial [27]. This
review summarizes the data on the predictive value of hsCRP for
ischemic stroke, analyzes the potential influence of CRP on func-
tional outcomes, and identifies the critical issues that are impor-
tant for the future studies.
2. CRP
CRP (protein CRP) is named because of its precipitation reaction
with phosphocholine moiety of pneumococcal cell wall C-
polysaccharide. According to the information on Ensembl data base
(http://useast.ensembl.org/Homo_sapiens/Gene/Summary?db=core;
g=ENSG00000132693;r=1:159712289–159714589), the CRP gene is
located on human chromosome 1, between 159,712,289 and
159,714,589 bps. It has 7 transcripts, of which 5 encode proteins.
Although the detailed functions of these protein variants are not fully
known, theproteinwith224 aaproducedby theCRP-001 transcript is
commonly known as the CRP protein. The protein is a member of the
pentraxin family of proteins. The pentraxins are an ancient family of
proteins with a unique architecture found as far back in evolution as
the Horseshoe crab. CRP structure is strong phylogenetic conserva-
tion and high resistance to proteolysis [28]. Therefore, it is relative
stable and easy to be measured.
Expression of CRP is regulatedmainly at the transcriptional level
by cytokines such as interleukin-1, interleukin-6, and tumor necro-
sis factor; among them, interleukin-6 is the primary circulating
physiologic mediator [26]. Recent studies have examined the
effects of IL-1b, the IL-1 receptor antagonist anakinra and the IL-6
receptor blocker tocilizumab on the regulation of expression of
CRP [29]. An estimation suggests that inter-individual variation in
blood CRP level is 35–40% heritable [30] and it is affected by gene
polymorphisms. The expression of CRP is also influenced by envi-
ronmental factors such as bacterial infection and injury. Plasma
CRP concentrations increase rapidly and dramatically (100-fold or
more) in response to tissue injury or inflammation. Therefore, high
levels of CRP (10–1000 mg/L), are associated with serious infections
or inflammatory diseases such as arthritis. The hsCRP, on the other
hand, measures CRP in the low range, from 0.5 to 10 mg/L. At such
range, the hsCRP test is used to identify low but persistent levels of
inflammation. The hsCRP is more precise than standard CRP when
measuring baseline concentrations. Induction of an hsCRP is rapid
and its half-life is long enough in the blood for a steady time course.
Therefore, plasma hsCRP is very useful for the diagnostic workup of
inflammatory and infectious diseases [26].
3. HsCRP level in early diagnosis of stroke
At present, the diagnosis of stroke depends on clinical examina-
tion and neuro-imaging techniques [31]. It is critically important to
identify effective biomarkers for the early diagnosis of acute stroke
and to establish biological procedures for early diagnosis [5]. Early
studies of different populations suggested that modest elevation of
hsCRP is a predictor of future vascular events in apparently healthy
individuals [32,33]. However, there are few data on the value of
hsCRP for the early diagnosis of ischemic stroke.
In 2012, Youn et al. reported in the Keran population that higher
hsCRP levels were associated with larger infarct volumes in AIS
(Table 1) [26]. Their results suggest that elevated hsCRP levelsmay serve as a helpful serologic marker in the evaluation of the
severity of AIS [34]. Kanai et al. investigated the reciprocal associ-
ation between serum levels of hsCRP (Table 1) and intercellular
adhesion molecule-1 (sICAM-1) and the risk of brain infarction in
type 2 diabetic patients [18]. Their study suggests that both mea-
surements of hsCRP and sICAM-1 levels are useful as a predictor
of future stroke in diabetic subjects [34]. However, these studies
are in Asian population. These findings have not been confirmed
in the other regions such as US and European countries.4. HsCRP in the prediction of atherosclerosis—artery stenosis or
occlusion
Ischaemic stroke accounts for 70–80% of all cases of stroke [35].
Ischaemic stroke is mainly caused by atherosclerosis and throm-
botic obstruction of cerebral blood flow (Table 1) [36,37].
Atherosclerosis, as a complex and systemic disease, may unequally
induce intracranial stenosis, which may in turn impose the limita-
tion of particular inflammatory mediator in describing atheroscle-
rosis [38,39]. Middle cerebral artery stenosis is also associated
with advanced age, hypertension, diabetes mellitus and hyperlipi-
daemia. The risk of stroke increases with the prevalence of
atherosclerosis. Therefore, identification of biomarkers for
atherosclerosis—artery stenosis or occlusion is essential for the
early prevention of stroke. Considerable studies have already shown
that an elevated serum CRP level reflects an increased tendency for
plaque rupture and a high atherosclerotic burden [13,32,33,40–42].
In 2011, Whiteley et al. showed that higher levels of hsCRP,
along with IL-6 and fibrinogen measured after stroke onset in
817 patients are significantly associated with increased incidence
of occlusive vascular events and vascular death, as well as nonva-
scular causes of death after stroke [43]. In a prospectively study of
intracranial large artery atherosclerosis progression in 25 of 75
patients using transcranial Doppler follow-up during a median
follow-up time of 23 months, Arenillas et al. reported that hsCRP
and plasminogen activator inhibitor-1 measured 3 months after
onset of ischemic stroke are highly predictive of intracranial large
artery atherosclerosis progression [44]. Similarly, Yoshida et al.
showed that CRP, along with IL-6 and protein-conjugated acrolein
(PC-Acro) is the risk factor for carotid atherosclerosis [45]. In a
study on the transcription levels of ABCA1, ABCG1 and SR–BI and
plasma CRP in Chinese populations with various risk factors for
atherosclerosis, Li et al. reported that circulating CRP was increased
almost in all the risk populations except in males [46]. Similarly,
hsCRP and Lp-PLA2 was found to improve ischemic stroke risk pre-
diction in the Atherosclerosis Risk in Communities study [47].
At the same time, there are also negative reports. In a study of
the association between inflammatory biomarkers and progression
of intracranial large artery stenosis after ischemic stroke, Shimizu
and colleagues reported that the Cox proportional hazard analysis
did not show a significant association between hsCRP and intracra-
nial large artery atherosclerosis progression. The authors con-
cluded that, because the effects of inflammatory factors may
continuously affect the vessel walls during the post stroke period,
the biomarkers may be more predictive in the chronic rather than
the acute stage of stroke and may be important for ILA progression
[41]. In a study of the influence of polyvascular atherothrombotic
disease on stroke patient prognosis, its relation with inflammatory
markers and the progression of atherothrombotic disease, Blanco
et al. found a non-significant trend to higher hsCRP levels in
patients with vascular recurrences [19]. The authors explained that
this is possibly because the calculation of the sample size was
based on incorrect assumptions regarding IL-6 levels [42].
The above data suggest that the hsCRP is associated with the
progression of atherosclerosis and possibly with artery stenosis
Table 1
Potential clinical applications of hsCRP level reported in literature.
Studies Phenotype CRP changes Effect and/or description
Xie et al. [13] Atherosclerosis Significantly high Patients with ICAO (internal carotid artery occlusion), MCAO (middle cerebral artery
occlusion) and ICAO + MCAO had significantly higher serum hsCRP concentrations
Youn et al. [26] Early diagnosis High Serve as a helpful serologic marker in the evaluation of the severity of AIS
Kanai et al. [34] >0.83 mg/L Measurement the risk of brain infarction in type 2 diabetic patients
Li et al. [48] Death risk High Independent predictor of long-term mortality after ischemic stroke in a Chinese sample
Chan et al. [52] >3.4 mg/L Most significant independent predictor of both short- and long-term mortality after
stroke
Huang et al. [50] >3.0 mg/L Elevated plasma hsCRP independently predicted risk of all-cause death within 3 months
after acute IS in Chinese patients
Makita et al. [12] High CRP levels can be used to predict future ischemic stroke and mortality in Japanese men
from the general population, independently from traditional cardiovascular risk factors
Tu et al. [49] High Independent predictors of short-term outcome and mortality after AIS
Elkind et al. [53] High Increase with stroke severity and may be associated with mortality to a greater degree
than recurrence
Liu et al. [58] Etiological
subtypes of IS
>6.96 mg/L Different among the subtypes and were the highest in CE(cardioembolism), followed by
LAA(large-artery atherosclerosis) and SAA (small-artery occlusion)
Ozkan et al. [27] Prognosis >0.5 mg/dL Predict functional disability 3 months after stroke onset
Gong et al. [60] >3.0 mg/L Elevated hsCRP independently predicts 1-year poor outcome in acute stroke
Park et al. [74] High hsCRP levels, along with MMP-9, TIMP-1 may be useful in the diagnosis of ischemic stroke
patients
Yeh et al. [40] High Serum level of hsCRP during both acute and convalescent phases was significantly and
independently predictive of 90-day MANE (major adverse neurological event)
Youn et al. [26] Higher Reflecting a large volume of infarct, may serve as a helpful serologic marker in the
evaluation of severity of acute ischemic stroke
Roudbary et al. [17] Hemorrhagic stroke Average About
10.7906 mg/L
hsCRP level is increase in patients with Ischemic infarct dramatically but not in
hemorrhagic stroke which might be considered as a usefully adjunct method for
determining type of stroke in patients with cerebrovascular problems
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hsCRP and the progression of atherosclerosis may be due to limited
sample size.5. hsCRP and death risk
An early risk assessment of the severity of disease and progno-
sis using biomarkers is pivotal for optimized care and the alloca-
tion of healthcare resources [48]. The predictability of death risk
for the stroke patients by hsCRP has been evaluated extensively
(Table 1). Current research indicated that expression of hsCRP
can be used to predict mortality from as short as three months
to as long as 5 year.
At least two studies have evaluated the value of hsCRP for pre-
dicting the risk of early death of stroke patients. In a prospective
study of 189 patients with AIS whowere admitted within 24 h after
the onset of symptoms, Tu et al. measured short-term functional
outcome by the modified Rankin scale (mRS), 90 days after admis-
sion. They concluded that hsCRP was independent predictor of
short-term outcome and mortality (Table 1) after AIS [49]. Huang
et al. (Table 1) found that elevated plasma hsCRP independently
predicted risk of all-cause death within 3 months after acute stroke
in Chinese patients. Compared with low hsCRP, patients with high
hsCRP (>3 mg/L) (Table 1) had a significantly higher rate of all-
cause death (0.71% vs. 10.00%; p < 0.001) at 3 months after stroke
onset [50]. Their study suggests that the level of hsCRP is a better
predictor of risk of death than for disease relapse. These studies sug-
gest that shortly after the onset of AIS, increased CRP levels may
reflect an accompanying inflammatory reaction. Elevated CRP levels
may reflect the extent of brain injury. Therefore, the elevated level
of hsCRP can predict the risk of early death of stroke patients.
Li and Liu prospectively studied one year outcomes in 374
patients with ischemic stroke who were admitted within 24 h after
the onset of symptoms. They measured serum levels of PCT, hsCRP
and NIH stroke scale of the patients at the time of admission. Clin-
ical follow-up was performed at 1 year. Their data showed that
hsCRP on admission was independent predictor of 1 year mortality
with an adjusted hazard ratio of 15.37 (95% confidence interval
[CI], 3.25–41.08) [48].Several prospective studies have demonstrated that high hsCRP
was an independent predictor of long-term mortality in patients
with stroke. Idicula et al. (Table 1) prospectively studied 498
patients with ischemic stroke who were admitted within 24 h after
the onset of symptoms [51]. Their investigation indicated that ele-
vated hsCRP concentration was an independent predictor of long-
term mortality over a period of 2.5 years after ischemic stroke
(p = 0.002). Their results also suggested that hsCRP concentration
was also an independent predictor of short-term mortality after
supratentorial intracerebral hemorrhage [51]. From a prospective
cohort study, Makita et al. (Table 1) found that baseline serum
hsCRP level was an independent predictor for future ischemic
stroke and all-cause mortality in apparently healthy Japanese
men. In their study, the mean follow-up period was 2.7 years [12].
The 5-year is the longest reported follow-up period. Chan et al.
[52] investigated biomarkers of various pathophysiologic path-
ways including hsCRP with mortality in stroke patients (Table 1).
During the 5-year follow-up, the mortality was 37.0% (34 out of
92). Authors concluded that hsCRP was the most significant inde-
pendent predictor of both short- and long-term mortality after
stroke. Mitchell et al. [53] admitted 467 patients with first
ischemic stroke; at 5-year follow-up, they concluded that hsCRP
was associated with risk of death. Similarly, several other reports
have suggested that increased hsCRP level is associated with high
risk of death stroke patients with variety of mortality rate. These
studies included Hartmann et al. (41.0% mortality rate) [54], Whit-
ing et al. (60.0% mortality rate) [55], Kammersgaard et al. (58.4%)
[56], and Putaala et al. (10.7%) [57].
At present, hsCRP is probably the only independent prognostic
factors in predicting both short- and long-term mortality.6. Application in etiological subtypes of ischemics stroke
Like many known disease, ischemic stroke is a group of diseases
with many different etiologies. At present, precise etiological clas-
sification depends heavily on the results of auxiliary examination.
However, most of these examinations are difficult to complete at
the early onset of a stroke because of the emergency nature of
the disease. Based on the TOAST etiology classification system,
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artery atherosclerosis (LAA), cardioembolism (CE), small-artery
occlusion (SAA), stroke of other determined etiology (SOE), and
stroke of undetermined etiology (SUE) [58,59]. As hsCRP levels
vary in apparently healthy population and in stroke patients, it
might be a useful marker for the ischemic stroke classification.
Liu et al. found that hsCRP and D-dimer levels were significantly
different among the subtypes and were the highest in CE (car-
dioembolism). Using the data, hsCRP > 6.96 mg/L was classified as
the CE subtype, with a sensitivity of 41% and a specificity of 74%
[58]. The authors suggested that using a combination of hsCRP
and DD may improve the diagnostic accuracy of CE in the acute
phase [58]. Future studies on this aspect will improve the classifi-
cation of the of stroke subtypes.7. hsCRP and prognosis
CRP levels strongly correlate with stroke severity and indepen-
dently predict mortality and stroke recurrence in AIS patients
(Table 1) [60], but only hsCRP is an independent predictor for unfa-
vorable outcome [61]. The level of hsCRP can predict the severity of
AIS patients. By examining the level of hsCRP in 316 patients with
AIS, Luo et al. found that elevated CRP level can reflect the severity
of AIS [61].
The different time points of blood sampling for the measure-
ment of hsCRP levels are also studied. Yeh et al. studies the hsCRP
levels during both acute and convalescent phases of 160 patients
[27]. They found that Hs-CRP levels during both acute phase and
convalescent phase of IS were significantly and independently pre-
dictive of 90-day major adverse neurological event (MANE) [27].
Authors also found that circulating level of hsCRP at 48 h was bet-
ter than the level at day 21 after acute IS for predictive of 90-day
MANE [27]. Their finding supports the validity of using serum
hsCRP level in predicting clinical outcome in patients with and
without IS regardless of the timing for blood sampling [27].
During the subacute phase of stroke, hsCRP values are associ-
ated with the level of functional disability. Song et al. examined
the hsCRP level in a total of 309 patients with first-ever stroke
within 24 h after symptom onset [62]. The hsCRP measurements
were made at admission and on the seventh hospital day. Their
study showed that both hsCRP values on admission and on the sev-
enth hospital day were significantly correlated with modified Ran-
kin Scale (mRS) scores obtained at 4 times after the onset of stroke.
Authors suggest that hsCRP values on the subacute phase have suf-
ficient value as predictors of the prognosis of functional disability
after first-ever stroke [62].
However, the prognostic value of hsCRP on stroke has its limita-
tions. Elkind et al. found that, after adjusting for confounders,
hsCRP was not associated with risk of recurrent stroke or recurrent
stroke, myocardial infarction, or vascular death but was associated
with risk of death [53]. In a study to investigate the association
between the progression of silent cerebral infarction (SCI) and
levels of soluble adhesion molecules and high-sensitivity C-
reactive protein (hsCRP) in type 2 diabetic patients, Kawamura
et al. reported that hsCRP was not associated with the progression
of SCI. By examining the hsCRP and ferritin levels of 62 patients
prospectively within 48 h after onset of ischemic stroke, Ozkan
et al. (Table 1) reported that neither hsCRP nor ferritin levels could
predict functional disability 3 months after stroke onset [27].8. CRP and hemorrhageic stroke
Studies so far indicate that hsCRP is not a predictive marker for
hemorrhagic stroke. Roudbary et al. assessed the concentration of
hsCRP in patients with documented ischemic and hemorrhagicstroke in the first 24 h of the onset of symptoms [17]. Their study
revealed that types of stroke were related to elevated hsCRP levels
[17]. Serum level of hsCRP (Table 1) in ischemic patients was
18.92 ± 11.28 and in hemorrhagic group was 2.65 ± 1.70. This dif-
ference was statistically significant (p < 0.0001) [17]. They con-
cluded that hsCRP level is increased in patients with ischemic
but not in hemorrhagic stroke, which may make it a useful adjunc-
tive method for determining type of stroke. At present other mark-
ers, but not hsCRP, are potentially used in the diagnosis of
hemorrhagic stroke.9. Other neurological and related conditions
In addition its prediction value in the stroke, hsCRP has also
been investigated for its prediction values in stroke relevant dis-
eases. Wersching et al. examined 447 community-dwelling and
stroke-free individuals from the Systematic Evaluation and Alter-
ation of Risk Factors for Cognitive Health (SEARCH) Study. They
found that serum CRP is linked to cerebral microstructural integ-
rity and cognitive function [63]. Song et al. examined 212 patients
with de novo Parkinson’s disease (PD), 253 patients with acute
ischemic cerebrovascular disease and 119 healthy subjects and
investigated the differences in hsCRP among these 3 groups. Their
results suggested that elevated hsCRP might have a clinical value
as a risk factor for Parkinson’s disease [15]. In a study of CRP and
lipid levels in women Everett et al. found that hsCRP associated
more closely with ischemic stroke than with CHD. They suggested
that concomitant evaluation of lipid levels and hsCRP may improve
risk assessment for stroke as well as CHD [11]. These and many
other studies have indicated that hsCRP is associated with large
number of diseases and disorders. Currently, the mechanistic link-
ages between CRP and these diseases are not completely
understood.10. CRP polymorphism influence the level of hsCRP
Like many other genes, the expression level of CRP is influenced
by its polymorphism [64] (Fig. 1). Polymorphism of CRP has been
investigated in different ethnic groups and different diseases. Sheu
et al. [65] measured CRP concentrations and investigated 6 poly-
morphisms of CRP gene in 369 Chinese men. They found that
CRP 1009A>G genotypes and associated haplotypes were associ-
ated with lower fasting serum hsCRP concentrations in a group
of elderly Chinese men. Liu et al. [66] then investigated the poten-
tial association of the CRP gene + 1444C/T polymorphism with
symptomatic carotid artery stenosis. They found that CRP + 1444
CC genotype is a risk factor for >70% carotid artery stenosis. The
serum CRP level was associated with the presence of carotid
stenosis.
Kettunen et al. investigated 5 polymorphisms and measured
CRP concentration of hsCRP in men in a Finnish middle-aged study
population. They found that CRP gene allelic variation is associated
with CRP levels in both sexes and with one carotid artery elasticity
parameter (SI) in men in a population-based Finnish cohort of
middle-aged subjects [64]. Assayag genotyped the 757T>C CRP
gene SNP and determined the concentration of serum CRP, the
intima-media thickness (IMT) of the common carotid artery and
the existence of plaque/s in 612 apparently healthy men and
women aged 66 ± 10 years in Israel [67]. Their study provided evi-
dence that CRP-757C allele of CRP gene is associated with carotid
atherosclerosis, independently of traditional vascular risk factors.
By studying the C1444T polymorphism of CRP 75 in consecutive
patients with a first-ever cerebral ischemic event attributable to
symptomatic intracranial atherosclerotic disease (ICAD) [68], Are-
nillas et al. suggested that presence of the T allele within the CRP
Fig. 1. Multiple factors determine the prediction function of hsCRP on stroke phenotypes. Level of hsCRP is influenced by its gene polymorphism, genomic background of the
ethnic groups, gender and it interacts with environment. These multiple factors interact each other to eventually determine the level of hsCRP. Accordingly, the level of hsCRP
achieves its values in whether it predicts different disease phenotypes.
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ther ischemic events in symptomatic ICAD patients.
Polymorphisms in other locations in the genome are also found
to influence the level of hsCRP. Bernardo et al. investigated the
Influence of the CD14 C260T promoter polymorphism on C-
reactive protein levels in patients with coronary artery disease
[69]. Their finding indicated that homozygosis status of the T allele
was independently associated with hsCRP levels and suggested
that T homozygotes of this functional polymorphism are at
increased ischemic risk.
However, there are negative reports suggest there is no associ-
ation of polymorphisms of CRP with disease. Ghattaset al reported
that CRP 1059G/C gene variation influences plasma CRP levels.
Conversely, this polymorphism was not associated with the risk
for acute myocardial infarction in an Egyptian population [70].
Huang assessed the potential genetic determinants for serum
hsCRP levels in a cohort with well-controlled nondiabetic hyper-
tension. They reported that CRP genotype had a limited effect on
serum hsCRP levels in subjects with well-controlled hypertension;
suggesting that the impacts of clinical rather than geneticdeterminants influence serum hsCRP levels for cardiovascular risk
stratification in this intermediate-risk Chinese Taiwanese cohort
[71].
These results above probably are the results of variation of func-
tion of the polymorphism, different ethnic genetic backgrounds,
and potential gene-environmental interaction.11. Ethnic difference on the prediction values of hsCRP
The predictive value of hsCRP may vary among different ethnic
groups (Fig. 1). At present, data on the early diagnosis based on the
expression level of hsCRP are all from Asian population [26,34]. The
reports on prediction values on diagnosis of disease recurrence and
major adverse neurological events are also from Asian population
[27,61,62]. Although the prediction of death rate is well recognized
among all ethnic groups, two studies that reported the prediction
values of hsCRP on the risk of early death of stroke patients are
all from Asian [49,50]. It is not clear whether it is true that some
polymorphism are only associated with men [64,65] while others
Table 2
Predictive values of CRP on different phenotypes.
Valuable Potentially valuable Unknown value Controversial
1. Death risk [12,48–50,52–57]
2. Etiological subtypes [58,59]
3. Early diagnosis [26,34]
4. Prognosis [26,27,40,60,74]
Atherosclerosis [13,46] 1. Idiopathic Parkinson’s disease [15]
2. Cerebral microstructural integrity and
cognitive function [63]
3. Hemorrhage [17]
1. Cognitive decline in late midlife [78]
2. Genetic determinants influence [71]
3. Functional disability [62,79–81]
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not have prediction values. The values of hsCRP expression level for
the prediction of atherosclerosis—artery stenosis or occlusion have
been recognized in a variety of ethnic groups. However, there is a
possibility that it predicts different phenotypes in different popu-
lations [35–47]. Therefore, it is most likely that the level of hsCRP
and its predication values on variety of stroke phenotypes are
influenced by the ethnic genome background.
12. Summary and future direction
It is clear that hsCRP has an important role in the prognosis and
risk factor prediction in stroke diseases, including long term and
short time death risk, early diagnosis, prediction of etiological sub-
types, and prognosis (Table 2). CRP is potentially valuable for the
prediction of atherosclerosis (Table 2). Its value on the prediction
is unknown for on idiopathic Parkinson’s disease, cerebral
microstructural integrity and cognitive function, and Hemorrhage.
Reports on its predictive value on functional disability, Cognitive
decline in late midlife, and genetic influence are controversial
(Table 2).
CRP expression and its predictive value are influenced by gene
polymorphisms [65], the genomic backgrounds of different racial
groups [26,27,35,46,50], sex and the environment (Fig. 1). There-
fore it is important to consider these factors when evaluating the
predictive value of hsCRP on stroke phenotypes in the future stud-
ies. These factors may also contribute to the controversial differ-
ences between studies in the value of hsCRP. Based on the
current report, hsCRP can be used in early diagnosis of stroke, pre-
diction of atherosclerosis—artery stenosis or occlusion, death risk,
and etiological subtypes of ischemic stroke.
In addition, hsCRP may be a valuable marker for some cere-
brovascular relevant diseases, but further investigation is neces-
sary. For example, the value of hsCRP levels as risk factors for the
initiation of Parkison’s disease [15]. Interestingly, in the prediction
of stroke prognosis, lesion volume and all of the evaluated bio-
chemical parameters are not deterministic factors [72].
In many studies, hsCRP has been investigated together with
other biomarkers. In order to increase the sensitivity and speci-
ficity of diagnosis, the combination of multi-biomarkers may be
necessary [5,27,34,41,47–49,53,58,62,73–75]. These markers may
together with hsCRP predict risk in different stages of the stroke
and/or phenotypes. For example, recent observations suggest that
measurement of serum MMP-9, TIMP-1, and hsCRP levels may be
useful in the diagnosis and management of ischemic stroke
patients providing a more feasible blood biomarker index [74].
Recently, the association between cerebrovascular disease and
adhesion molecules has received much attention. A study suggests
that sICAM-1 levels may be a potential marker for silent cerebral
infarction, which may lead to future stroke and vascular dementia,
and that this marker could be useful in monitoring disease progres-
sion and as a surrogate marker in treatment studies [75,76].
Lowering CRP levels may be of value in stroke patients or those
with other relevant diseases. It has been reported that statin ther-
apy significantly alters serum hsCRP level in patient after acute
ischemic stroke [14]. While more studies may be necessary todetermine whether statins improve the clinical outcome among
patients with AIS with elevated CRP levels [26], statins should be
given as early as possible in patients with acute ischemic stroke,
especially those with high hsCRP concentrations [14].
Quick and accurate detection methods for CRP levels should be
developed. For example, a real-time, on-line and low-cost wide-
range -CRP assay is a reasonable alternative to the Behring Dade
hsCRP method in acute stroke/transient ischemic attack patients
[77].
There are several important questions regarding the role of CRP
polymorphisms. It is important to understand whether polymor-
phisms affect the expression level or function of the CRP, whether
the altered level of CRP reflect the risk level in stroke disease, and
whether single plays a key role or multiple polymorphisms act
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